

**TDMs No.** 99017 - 06

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS  
ABRIDGED) (a)**

**Date Report Requested:** 10/23/2008

**Test Type:** CHRONIC

Diethylamine

**Time Report Requested:** 13:20:12

**Route:** RESPIRATORY EXPOSURE WHOLE BODY

**CAS Number:** 109-89-7

**First Dose M/F:** 08/18/03 / 08/18/03

**Species/Strain:** MICE/B6C3F1

**Lab:** BNW

F1\_M3

**C Number:** C99017

**Lock Date:** 08/01/2006

**Cage Range:** ALL

**Date Range:** ALL

**Reasons For Removal:** ALL

**Removal Date Range:** ALL

**Treatment Groups:** Include ALL

**Study Gender:** Both

**TDMSE Version:** 2.0.0

Test Type: CHRONIC

Time Report Requested: 13:20:12

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 109-89-7

First Dose M/F: 08/18/03 / 08/18/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Disposition Summary</b>				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	15	10	12	11
Natural Death	4	2	6	2
Survivors				
Terminal Sacrifice	31	38	32	37
Animals Examined Microscopically	50	50	50	50
<b>ALIMENTARY SYSTEM</b>				
Gallbladder	(36)	(42)	(41)	(38)
Adenoma			1 (2%)	
Intestine Large, Cecum	(50)	(50)	(50)	(50)
Carcinoma		1 (2%)	1 (2%)	
Intestine Large, Colon	(50)	(50)	(50)	(50)
Serosa, Carcinoma, Metastatic, Pancreas		1 (2%)		
Intestine Large, Rectum	(50)	(50)	(50)	(50)
Intestine Small, Duodenum	(49)	(50)	(50)	(50)
Serosa, Carcinoma, Metastatic, Pancreas		1 (2%)		
Intestine Small, Ileum	(50)	(50)	(50)	(50)
Carcinoma		1 (2%)		
Hemangiosarcoma			1 (2%)	
Polyp Adenomatous				1 (2%)
Serosa, Carcinoma, Metastatic, Pancreas		1 (2%)		
Intestine Small, Jejunum	(50)	(50)	(50)	(50)
Carcinoma	2 (4%)			1 (2%)
Serosa, Sarcoma, Metastatic, Uncertain Primary Site	1 (2%)			
Liver	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Pancreas		1 (2%)		
Hemangiosarcoma	2 (4%)	1 (2%)	4 (8%)	1 (2%)
Hepatoblastoma	1 (2%)	1 (2%)		
Hepatocellular Adenoma	14 (28%)	21 (42%)	15 (30%)	20 (40%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Diethylamine

Time Report Requested: 13:20:12

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 109-89-7

First Dose M/F: 08/18/03 / 08/18/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	16 PPM	31 PPM	62.5 PPM
Hepatocellular Adenoma, Multiple	14 (28%)	8 (16%)	13 (26%)	11 (22%)
Hepatocellular Carcinoma	14 (28%)	14 (28%)	11 (22%)	16 (32%)
Hepatocellular Carcinoma, Multiple	6 (12%)	3 (6%)	3 (6%)	4 (8%)
Mesentery	(10)	(6)	(4)	(8)
Carcinoma, Metastatic, Pancreas		1 (17%)		
Carcinoma, Metastatic, Uncertain Primary Site			1 (25%)	
Hemangiosarcoma	1 (10%)			3 (38%)
Hepatoblastoma, Metastatic, Liver	1 (10%)			
Sarcoma, Metastatic, Uncertain Primary Site	1 (10%)			
Pancreas	(50)	(50)	(49)	(50)
Carcinoma		1 (2%)		
Sarcoma, Metastatic, Uncertain Primary Site	1 (2%)			
Salivary Glands	(50)	(50)	(50)	(50)
Fibrous Histiocytoma, Metastatic, Skin				1 (2%)
Sarcoma				1 (2%)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Squamous Cell Carcinoma	2 (4%)			
Squamous Cell Papilloma				1 (2%)
Stomach, Glandular	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Pancreas		1 (2%)		
Tooth	(6)	(6)	(8)	(5)
Odontoma	2 (33%)	3 (50%)	3 (38%)	

## CARDIOVASCULAR SYSTEM

Blood Vessel	(0)	(1)	(0)	(1)
Aorta, Carcinoma, Metastatic, Pancreas		1 (100%)		
Heart	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Pancreas		1 (2%)		
Hemangiosarcoma	1 (2%)	1 (2%)	1 (2%)	
Hepatoblastoma, Metastatic, Liver	1 (2%)			
Hepatocellular Carcinoma, Metastatic, Liver			2 (4%)	
Sarcoma, Metastatic, Uncertain Primary Site			1 (2%)	
Pericardium, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Diethylamine

Time Report Requested: 13:20:12

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 109-89-7

First Dose M/F: 08/18/03 / 08/18/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>ENDOCRINE SYSTEM</b>				
Adrenal Cortex	(50)	(50)	(50)	(50)
Adenoma	1 (2%)	3 (6%)	2 (4%)	1 (2%)
Carcinoma, Metastatic, Pancreas		1 (2%)		
Capsule, Sarcoma, Metastatic, Uncertain Primary Site	1 (2%)			
Subcapsular, Adenoma	5 (10%)	2 (4%)	4 (8%)	1 (2%)
Adrenal Medulla	(50)	(50)	(50)	(50)
Pheochromocytoma Benign				1 (2%)
Islets, Pancreatic	(50)	(50)	(49)	(50)
Adenoma	2 (4%)	1 (2%)		1 (2%)
Carcinoma				1 (2%)
Carcinoma, Metastatic, Pancreas		1 (2%)		
Parathyroid Gland	(28)	(32)	(25)	(21)
Pituitary Gland	(50)	(50)	(49)	(50)
Pars Distalis, Oligodendroglioma Malignant, Metastatic, Brain			1 (2%)	
Thyroid Gland	(50)	(50)	(48)	(49)
Sarcoma, Metastatic, Skeletal Muscle				1 (2%)
Follicular Cell, Adenoma		2 (4%)		
<b>GENERAL BODY SYSTEM</b>				
Peritoneum	(1)	(0)	(0)	(0)
<b>GENITAL SYSTEM</b>				
Coagulating Gland	(0)	(1)	(0)	(0)
Carcinoma, Metastatic, Pancreas		1 (100%)		
Epididymis	(49)	(50)	(50)	(50)
Carcinoma, Metastatic, Pancreas		1 (2%)		
Fibrous Histiocytoma, Metastatic, Skin				1 (2%)
Hemangiosarcoma		1 (2%)		
Penis	(0)	(0)	(0)	(2)
Preputial Gland	(50)	(50)	(50)	(50)
Fibrous Histiocytoma, Metastatic, Skin				1 (2%)
Prostate	(50)	(50)	(50)	(49)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Diethylamine

Time Report Requested: 13:20:12

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 109-89-7

First Dose M/F: 08/18/03 / 08/18/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	16 PPM	31 PPM	62.5 PPM
Carcinoma, Metastatic, Pancreas		1 (2%)		
Fibrous Histiocytoma, Metastatic, Skin				1 (2%)
Seminal Vesicle	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Pancreas		1 (2%)		
Testes	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Pancreas		1 (2%)		
Fibrous Histiocytoma, Metastatic, Skin				1 (2%)
<b>HEMATOPOIETIC SYSTEM</b>				
Bone Marrow	(50)	(50)	(50)	(50)
Fibrous Histiocytoma, Metastatic, Skin				1 (2%)
Hemangiosarcoma	2 (4%)	2 (4%)		
Oligodendroglioma Malignant, Metastatic, Brain			1 (2%)	
Lymph Node	(0)	(5)	(5)	(0)
Carcinoma, Metastatic, Pancreas		1 (20%)		
Iliac, Sarcoma, Metastatic, Uncertain Primary Site			1 (20%)	
Renal, Hemangiosarcoma		1 (20%)		
Lymph Node, Bronchial	(20)	(29)	(25)	(25)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (5%)			
Carcinoma, Metastatic, Pancreas		1 (3%)		
Hepatoblastoma, Metastatic, Liver	1 (5%)			
Hepatocellular Carcinoma, Metastatic, Liver	1 (5%)		1 (4%)	1 (4%)
Lymph Node, Mandibular	(16)	(20)	(18)	(20)
Hemangiosarcoma		1 (5%)		
Lymph Node, Mediastinal	(33)	(35)	(36)	(38)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (3%)			
Carcinoma, Metastatic, Pancreas		1 (3%)		
Hepatoblastoma, Metastatic, Liver	1 (3%)			
Hepatocellular Carcinoma, Metastatic, Liver	1 (3%)		1 (3%)	
Sarcoma, Metastatic, Uncertain Primary Site	1 (3%)			
Lymph Node, Mesenteric	(49)	(47)	(48)	(50)
Carcinoma, Metastatic, Intestine Large,		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Diethylamine

Time Report Requested: 13:20:12

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 109-89-7

First Dose M/F: 08/18/03 / 08/18/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	16 PPM	31 PPM	62.5 PPM
Cecum				
Carcinoma, Metastatic, Pancreas		1 (2%)		
Carcinoma, Metastatic, Uncertain Primary Site			1 (2%)	
Hemangiosarcoma				1 (2%)
Spleen	(50)	(50)	(49)	(50)
Hemangiosarcoma	3 (6%)	4 (8%)	4 (8%)	1 (2%)
Thymus	(38)	(36)	(36)	(37)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (3%)			1 (3%)
Hepatoblastoma, Metastatic, Liver	1 (3%)			
Hepatocellular Carcinoma, Metastatic, Liver			1 (3%)	
Sarcoma, Metastatic, Uncertain Primary Site	1 (3%)		1 (3%)	
<b>INTEGUMENTARY SYSTEM</b>				
Skin	(50)	(50)	(49)	(50)
Subcutaneous Tissue, Fibroma			1 (2%)	
Subcutaneous Tissue, Fibrous Histiocytoma		2 (4%)		1 (2%)
Subcutaneous Tissue, Hemangiosarcoma	1 (2%)	1 (2%)	1 (2%)	
Subcutaneous Tissue, Sarcoma	1 (2%)			
<b>MUSCULOSKELETAL SYSTEM</b>				
Bone	(50)	(50)	(49)	(50)
Hemangiosarcoma	1 (2%)	1 (2%)		
Maxilla, Carcinoma, Metastatic, Harderian Gland				1 (2%)
Skeletal Muscle	(2)	(3)	(3)	(1)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (50%)			
Carcinoma, Metastatic, Pancreas		1 (33%)		
Hemangiosarcoma		1 (33%)	2 (67%)	
Sarcoma				1 (100%)
Sarcoma, Metastatic, Uncertain Primary	1 (50%)		1 (33%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Diethylamine

Time Report Requested: 13:20:12

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 109-89-7

First Dose M/F: 08/18/03 / 08/18/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	16 PPM	31 PPM	62.5 PPM
Site				
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Harderian Gland				2 (4%)
Fibrous Histiocytoma, Metastatic, Skin				1 (2%)
Meningioma Benign	1 (2%)			
Oligodendroglioma Malignant			1 (2%)	
Peripheral Nerve	(0)	(1)	(1)	(0)
RESPIRATORY SYSTEM				
Larynx	(50)	(50)	(50)	(50)
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	4 (8%)	4 (8%)	5 (10%)	3 (6%)
Alveolar/Bronchiolar Carcinoma	12 (24%)	10 (20%)	9 (18%)	9 (18%)
Alveolar/Bronchiolar Carcinoma, Multiple			1 (2%)	
Carcinoma, Metastatic, Harderian Gland		1 (2%)		
Carcinoma, Metastatic, Intestine Small, Jejunum	1 (2%)			
Carcinoma, Metastatic, Pancreas		1 (2%)		
Hemangiosarcoma			1 (2%)	
Hepatoblastoma, Metastatic, Liver	1 (2%)	1 (2%)		
Hepatocellular Carcinoma, Metastatic, Liver	8 (16%)	6 (12%)	6 (12%)	9 (18%)
Sarcoma, Metastatic, Uncertain Primary Site	1 (2%)		1 (2%)	
Nose	(50)	(50)	(50)	(50)
Fibrous Histiocytoma, Metastatic, Skin				1 (2%)
Oligodendroglioma Malignant, Metastatic, Brain			1 (2%)	
Pleura	(1)	(0)	(0)	(0)
Trachea	(50)	(50)	(50)	(50)
Sarcoma, Metastatic, Skeletal Muscle				1 (2%)
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Diethylamine

Time Report Requested: 13:20:12

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 109-89-7

First Dose M/F: 08/18/03 / 08/18/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	16 PPM	31 PPM	62.5 PPM
Harderian Gland	(50)	(50)	(50)	(50)
Adenoma	4 (8%)	6 (12%)	2 (4%)	1 (2%)
Carcinoma	4 (8%)	7 (14%)	1 (2%)	3 (6%)
<b>URINARY SYSTEM</b>				
Kidney	(50)	(50)	(49)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (2%)	1 (2%)		
Carcinoma, Metastatic, Pancreas		1 (2%)		
Hepatocellular Carcinoma, Metastatic, Liver			1 (2%)	
Sarcoma, Metastatic, Uncertain Primary Site	1 (2%)		1 (2%)	
Renal Tubule, Adenoma			1 (2%)	
Renal Tubule, Carcinoma			1 (2%)	
Urethra	(0)	(0)	(1)	(0)
Bulbourethral Gland, Carcinoma			1 (100%)	
Urinary Bladder	(50)	(50)	(49)	(50)
<b>SYSTEMIC LESIONS</b>				
Multiple Organs	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	1 (2%)	2 (4%)	1 (2%)	1 (2%)
Lymphoma Malignant	2 (4%)	3 (6%)	3 (6%)	
Mesothelioma Malignant	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically



Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

CAS Number: 109-89-7

Time Report Requested: 13:20:12

First Dose M/F: 08/18/03 / 08/18/03

Lab: BNW

B6C3F1 MICE MALE	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Tumor Summary for Males</b>				
Total Animals with Primary Neoplasms (b)	48	46	47	44
Total Primary Neoplasms	104	109	94	85
Total Animals with Benign Neoplasms	33	34	34	34
Total Benign Neoplasms	47	50	47	41
Total Animals with Malignant Neoplasms	36	34	31	32
Total Malignant Neoplasms	57	59	47	44
Total Animals with Metastatic Neoplasms	12	10	8	14
Total Metastatic Neoplasms	42	32	23	24
Total Animals with Malignant Neoplasms Uncertain Primary Site	1		1	
Total Animals with Neoplasms Uncertain-Benign or Malignant				
Total Uncertain Neoplasms				

\*\*\* END OF MALE \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Test Type: CHRONIC

Time Report Requested: 13:20:12

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 109-89-7

First Dose M/F: 08/18/03 / 08/18/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Disposition Summary</b>				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	13	11	7	10
Natural Death	5	4	7	1
Survivors				
Terminal Sacrifice	32	35	36	39
Animals Examined Microscopically	50	50	50	50
<b>ALIMENTARY SYSTEM</b>				
Esophagus	(50)	(50)	(50)	(50)
Gallbladder	(38)	(45)	(44)	(42)
Intestine Large, Cecum	(50)	(50)	(50)	(50)
Leiomyoma	1 (2%)			
Polyp Adenomatous		1 (2%)		
Intestine Large, Rectum	(50)	(50)	(50)	(50)
Intestine Small, Duodenum	(50)	(50)	(49)	(50)
Intestine Small, Ileum	(50)	(50)	(50)	(50)
Sarcoma				1 (2%)
Intestine Small, Jejunum	(50)	(50)	(50)	(50)
Polyp Adenomatous			1 (2%)	
Liver	(50)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)	1 (2%)		
Hepatocellular Adenoma	8 (16%)	14 (28%)	14 (28%)	10 (20%)
Hepatocellular Adenoma, Multiple	6 (12%)	5 (10%)	3 (6%)	
Hepatocellular Carcinoma	2 (4%)	5 (10%)	6 (12%)	1 (2%)
Hepatocellular Carcinoma, Multiple	2 (4%)		1 (2%)	1 (2%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle				1 (2%)
Mesentery	(12)	(16)	(15)	(10)
Carcinoma, Metastatic, Urinary Bladder				1 (10%)
Hemangiosarcoma	2 (17%)			1 (10%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle				1 (10%)
Sarcoma, Metastatic, Intestine Small, Ileum				1 (10%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Diethylamine

Time Report Requested: 13:20:12

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 109-89-7

First Dose M/F: 08/18/03 / 08/18/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	16 PPM	31 PPM	62.5 PPM
Sarcoma, Metastatic, Skin	1 (8%)		1 (7%)	
Oral Mucosa	(1)	(0)	(0)	(0)
Pancreas	(50)	(50)	(50)	(50)
Adenoma			1 (2%)	
Carcinoma, Metastatic, Urinary Bladder				1 (2%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle				1 (2%)
Sarcoma, Metastatic, Intestine Small, Ileum				1 (2%)
Sarcoma, Metastatic, Skin	1 (2%)			
Salivary Glands	(49)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Sarcoma, Metastatic, Skin			1 (2%)	
Squamous Cell Carcinoma	1 (2%)			
Squamous Cell Papilloma			1 (2%)	1 (2%)
Stomach, Glandular	(50)	(50)	(50)	(50)
Tooth	(0)	(0)	(0)	(1)
<b>CARDIOVASCULAR SYSTEM</b>				
Blood Vessel	(2)	(0)	(1)	(0)
Heart	(50)	(50)	(50)	(50)
<b>ENDOCRINE SYSTEM</b>				
Adrenal Cortex	(50)	(50)	(50)	(50)
Adenoma	1 (2%)	1 (2%)		
Subcapsular, Adenoma		1 (2%)		2 (4%)
Adrenal Medulla	(50)	(50)	(50)	(49)
Pheochromocytoma Benign		1 (2%)		1 (2%)
Pheochromocytoma Malignant		1 (2%)	1 (2%)	
Islets, Pancreatic	(50)	(50)	(50)	(50)
Adenoma				1 (2%)
Parathyroid Gland	(23)	(32)	(33)	(33)
Pituitary Gland	(50)	(50)	(50)	(49)
Pars Distalis, Adenoma	10 (20%)	5 (10%)	6 (12%)	7 (14%)
Pars Distalis, Carcinoma		1 (2%)		
Pars Distalis, Schwannoma Malignant, Metastatic, Uncertain Primary Site			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Diethylamine

Time Report Requested: 13:20:12

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 109-89-7

First Dose M/F: 08/18/03 / 08/18/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	16 PPM	31 PPM	62.5 PPM
Pars Intermedia, Adenoma	2 (4%)	1 (2%)		1 (2%)
Thyroid Gland	(50)	(50)	(50)	(50)
Follicular Cell, Adenoma		1 (2%)	1 (2%)	
<b>GENERAL BODY SYSTEM</b>				
Peritoneum	(0)	(0)	(0)	(1)
<b>GENITAL SYSTEM</b>				
Clitoral Gland	(46)	(43)	(43)	(46)
Sarcoma, Metastatic, Skin	1 (2%)	1 (2%)		
Ovary	(49)	(50)	(50)	(50)
Carcinoma, Metastatic, Mammary Gland	1 (2%)			
Cystadenocarcinoma		1 (2%)		
Cystadenoma	3 (6%)	2 (4%)		
Hemangiosarcoma	1 (2%)			
Luteoma		1 (2%)	1 (2%)	1 (2%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle				1 (2%)
Periovarian Tissue, Carcinoma, Metastatic, Urinary Bladder				1 (2%)
Uterus	(50)	(50)	(50)	(50)
Cystadenocarcinoma, Metastatic, Ovary		1 (2%)		
Hemangiosarcoma				1 (2%)
Leiomyoma		1 (2%)		1 (2%)
Polyp Stromal	1 (2%)	2 (4%)	2 (4%)	
Sarcoma, Metastatic, Intestine Small, Ileum				1 (2%)
Sarcoma Stromal		1 (2%)		
Vagina	(0)	(0)	(1)	(0)
<b>HEMATOPOIETIC SYSTEM</b>				
Bone Marrow	(50)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)	1 (2%)		
Lymph Node	(5)	(6)	(11)	(5)
Iliac, Hemangiosarcoma		1 (17%)		
Lymph Node, Bronchial	(29)	(32)	(31)	(38)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Diethylamine

Time Report Requested: 13:20:12

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 109-89-7

First Dose M/F: 08/18/03 / 08/18/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	16 PPM	31 PPM	62.5 PPM
Carcinoma, Metastatic, Mammary Gland	1 (3%)			
Hemangiosarcoma	1 (3%)			
Lymph Node, Mandibular	(23)	(40)	(30)	(33)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (4%)			
Mast Cell Tumor Malignant, Metastatic, Uncertain Primary Site				1 (3%)
Lymph Node, Mediastinal	(34)	(33)	(44)	(40)
Sarcoma, Metastatic, Intestine Small, Ileum				1 (3%)
Sarcoma, Metastatic, Skin	1 (3%)		1 (2%)	
Lymph Node, Mesenteric	(50)	(46)	(46)	(49)
Carcinoma, Metastatic, Urinary Bladder				1 (2%)
Hemangiosarcoma	1 (2%)			
Sarcoma, Metastatic, Intestine Small, Ileum				1 (2%)
Spleen	(50)	(50)	(50)	(50)
Hemangiosarcoma	2 (4%)			
Capsule, Carcinoma, Metastatic, Urinary Bladder				1 (2%)
Capsule, Rhabdomyosarcoma, Metastatic, Skeletal Muscle				1 (2%)
Thymus	(47)	(47)	(45)	(47)
Sarcoma, Metastatic, Intestine Small, Ileum				1 (2%)
<b>INTEGUMENTARY SYSTEM</b>				
Mammary Gland	(50)	(50)	(50)	(49)
Carcinoma	4 (8%)	1 (2%)	2 (4%)	
Fibroadenoma	1 (2%)			
Sarcoma, Metastatic, Skin		1 (2%)		
Skin	(50)	(50)	(50)	(50)
Squamous Cell Carcinoma		1 (2%)	1 (2%)	
Subcutaneous Tissue, Fibrous		1 (2%)		
Histiocytoma				
Subcutaneous Tissue, Hemangiosarcoma		1 (2%)		
Subcutaneous Tissue, Sarcoma	3 (6%)	1 (2%)	5 (10%)	2 (4%)
Subcutaneous Tissue, Sarcoma, Multiple	1 (2%)		1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Diethylamine

Time Report Requested: 13:20:12

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 109-89-7

First Dose M/F: 08/18/03 / 08/18/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>MUSCULOSKELETAL SYSTEM</b>				
Bone	(49)	(50)	(50)	(49)
Sarcoma, Metastatic, Skin	1 (2%)			
Cranium, Schwannoma Malignant, Metastatic, Uncertain Primary Site			1 (2%)	
Skeletal Muscle	(1)	(2)	(2)	(3)
Carcinoma, Metastatic, Urinary Bladder				1 (33%)
Rhabdomyosarcoma		1 (50%)		1 (33%)
Sarcoma, Metastatic, Skin	1 (100%)			
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(50)	(50)	(50)
Meninges, Carcinoma, Metastatic, Pituitary Gland		1 (2%)		
Meninges, Schwannoma Malignant, Metastatic, Uncertain Primary Site			1 (2%)	
Peripheral Nerve	(0)	(2)	(0)	(1)
Spinal Cord	(1)	(1)	(0)	(1)
Sarcoma, Metastatic, Skin	1 (100%)			
<b>RESPIRATORY SYSTEM</b>				
Larynx	(50)	(50)	(50)	(50)
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	2 (4%)	3 (6%)	1 (2%)	4 (8%)
Alveolar/Bronchiolar Adenoma, Multiple			1 (2%)	
Alveolar/Bronchiolar Carcinoma	3 (6%)	1 (2%)	4 (8%)	1 (2%)
Carcinoma, Metastatic, Mammary Gland	1 (2%)			
Hepatocellular Carcinoma, Metastatic, Liver	2 (4%)	2 (4%)	2 (4%)	1 (2%)
Sarcoma, Metastatic, Skin			1 (2%)	
Mediastinum, Hemangiosarcoma	1 (2%)			
Nose	(50)	(49)	(50)	(50)
Trachea	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Time Report Requested: 13:20:12

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 109-89-7

First Dose M/F: 08/18/03 / 08/18/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>SPECIAL SENSES SYSTEM</b>				
Eye	(50)	(50)	(50)	(50)
Harderian Gland	(50)	(50)	(50)	(50)
Adenoma	3 (6%)	1 (2%)		5 (10%)
Carcinoma	2 (4%)	1 (2%)		4 (8%)
<b>URINARY SYSTEM</b>				
Kidney	(50)	(50)	(50)	(50)
Urinary Bladder	(50)	(50)	(49)	(50)
Transitional Epithelium, Carcinoma				1 (2%)
<b>SYSTEMIC LESIONS</b>				
Multiple Organs	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	1 (2%)			1 (2%)
Lymphoma Malignant	8 (16%)	15 (30%)	15 (30%)	13 (26%)

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

Time Report Requested: 13:20:12

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 109-89-7

First Dose M/F: 08/18/03 / 08/18/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Tumor Summary for Females</b>				
Total Animals with Primary Neoplasms (b)	41	40	40	41
Total Primary Neoplasms	75	75	68	62
Total Animals with Benign Neoplasms	25	28	26	26
Total Benign Neoplasms	38	40	32	34
Total Animals with Malignant Neoplasms	23	28	29	26
Total Malignant Neoplasms	37	35	36	28
Total Animals with Metastatic Neoplasms	7	5	5	5
Total Metastatic Neoplasms	13	6	9	19
Total Animals with Malignant Neoplasms Uncertain Primary Site			1	1
Total Animals with Neoplasms Uncertain-Benign or Malignant				
Total Uncertain Neoplasms				

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors